Merus and Halozyme link on subcutaneous petosemtamab
Merus will pay Halozyme an upfront fee, milestone payments and low to mid single-digit royalties on net sales.
Drug Development
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
BostonGene and Kyoto University link on oesophageal cancer drug
AHA 2025: Gene therapy shows potential in chronic heart failure
Harbour BioMed and Evinova collaborate on AI biologics
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases
Abzena and Mabqi partner for drug development solution
